Literature DB >> 8248932

Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats.

S R Thom1.   

Abstract

Exposure to hyperbaric oxygen [3 atmospheres absolute (ATA) for 45 min] inhibited carbon monoxide (CO)-mediated lipid peroxidation in the brains of rats by preventing the conversion of xanthine dehydrogenase to oxidase, a conversion process known to be due to the action of leukocytes. The effect was the same whether treatment was given 24 hr before or up to 45 min after poisoning. Hyperbaric oxygen did not inhibit the initial interaction of leukocytes with brain microvasculature, based on measurements of myeloperoxidase (MPO) in microvessel segments, but persistent adherence, which is due to B2 integrins, did not occur. Exposing rats to 3 ATA pressure (0.21 ATA O2) after CO poisoning had no significant effects. A progressive reduction in brain microvessel MPO titers occurred with exposure to O2 at 1, 2, or 3 ATA after CO poisoning, but 1 ATA O2 treatment did not significantly inhibit xanthine oxidase formation or lipid peroxidation. In vitro studies with polymorphonuclear leukocytes (PMN) from rats exposed to hyperbaric oxygen corroborated the absence of PMN B2 integrin function, but when these cells were stimulated they exhibited normal B2 integrin expression on their surface and also normal elastase release and superoxide radical production. Adherence functions of PMN that do not require B2 integrins appeared to remain intact after exposure to hyperbaric oxygen, as peritoneal neutrophilia in response to a glycogen challenge was not inhibited. B2 integrin function could be restored by incubating cells with 8 bromo cGMP, and incubation with phorbol ester stimulated the adherence function of both control and hyperbaric oxygen-exposed PMN. These results provide a clear mechanism for the inhibition of CO-mediated brain lipid peroxidation by hyperbaric oxygen and indicate that hyperoxia causes a discrete disturbance of PMN adherence function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8248932     DOI: 10.1006/taap.1993.1243

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  31 in total

Review 1.  Carbon monoxide poisoning: an update.

Authors:  M Turner; M R Hamilton-Farrell; R J Clark
Journal:  J Accid Emerg Med       Date:  1999-03

2.  Hyperbaric oxygen in systemic inflammatory response.

Authors:  Haim Bitterman; Claus-Martin Muth
Journal:  Intensive Care Med       Date:  2004-03-18       Impact factor: 17.440

3.  Thioredoxin reductase linked to cytoskeleton by focal adhesion kinase reverses actin S-nitrosylation and restores neutrophil β(2) integrin function.

Authors:  Stephen R Thom; Veena M Bhopale; Tatyana N Milovanova; Ming Yang; Marina Bogush
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

4.  Hyperbaric oxygen pretreatment reduces the incidence of decompression sickness in rats.

Authors:  Ksenya Katsenelson; Yehuda Arieli; Amir Abramovich; Moshe Feinsod; Ran Arieli
Journal:  Eur J Appl Physiol       Date:  2007-08-03       Impact factor: 3.078

5.  Hyperbaric oxygen and sepsis: time to recognize.

Authors:  Claus-Martin Muth; Peter Radermacher; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2005-07-21       Impact factor: 17.440

6.  Hyperbaric oxygen therapy and liver transplantation.

Authors:  Vijayaragavan Muralidharan; Chris Christophi
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  [Hyperbaric oxygen for carbon monoxide poisoning: case report of severe poisoning due to exhaust fumes].

Authors:  M Erdmann; H Schöppenthau; J Büttner
Journal:  Anaesthesist       Date:  2009-06       Impact factor: 1.041

Review 8.  Oxidative stress is fundamental to hyperbaric oxygen therapy.

Authors:  Stephen R Thom
Journal:  J Appl Physiol (1985)       Date:  2008-10-09

Review 9.  Hyperbaric oxygen chambers and the treatment of sports injuries.

Authors:  J Staples; D Clement
Journal:  Sports Med       Date:  1996-10       Impact factor: 11.136

Review 10.  Bench-to-bedside review: oxygen as a drug.

Authors:  Haim Bitterman
Journal:  Crit Care       Date:  2009-02-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.